Den Europæiske Union - dansk - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastiske midler - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatic neoplasmer, kastration-resistent - antineoplastiske midler - treatment of adult patients with prostate cancer.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - verapamilhydrochlorid - depottabletter - 240 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

hexal a/s - verapamilhydrochlorid - filmovertrukne tabletter - 120 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

hexal a/s - verapamilhydrochlorid - filmovertrukne tabletter - 40 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

hexal a/s - verapamilhydrochlorid - filmovertrukne tabletter - 80 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - verapamilhydrochlorid - filmovertrukne tabletter - 80 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - verapamilhydrochlorid - filmovertrukne tabletter - 120 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - verapamilhydrochlorid - filmovertrukne tabletter - 120 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pharmaand gmbh - rucaparib camsylate - Æggestokkene neoplasmer - antineoplastiske midler - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca er angivet som monoterapi til vedligeholdelse behandling af voksne patienter med platin-følsomme gået high-grade epitelial ovariecancer, æggeleder, eller primær peritoneal cancer, der er i reaktion (hel eller delvis) til platin-baseret kemoterapi.